for a summary of our marketed products and clinical development programs. Since our incorporation in January 2012, our operations to date have included organizing and staffing our company, business planning, raising capital, developing our compounds, engaging in other discovery and preclinical activities, the commercial launches of AUVELITY and SUNOSI, and preparatory activities for the launch of SYMBRAVO. Subsequent to our IPO, we financed our operations primarily through proceeds from sales of...
Q2 FY2026 — expected 2026-08-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-23 | 2025-12-31 | 0001193125-26-064267 | EDGAR | 107K words |
| 2025-02-18 | 2024-12-31 | 0000950170-25-022457 | EDGAR | — |
| 2024-02-23 | 2023-12-31 | 0000950170-24-019118 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0000950170-23-004728 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0000950170-22-002568 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001564590-21-009924 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001558370-20-002573 | EDGAR | — |
| 2019-03-15 | 2018-12-31 | 0001558370-19-002068 | EDGAR | — |
| 2018-03-07 | 2017-12-31 | 0001558370-18-001639 | EDGAR | — |
| 2017-03-07 | 2016-12-31 | 0001558370-17-001426 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-03 | 2025-09-30 | 0001193125-25-262664 | EDGAR | 72K words |
| 2025-08-04 | 2025-06-30 | 0000950170-25-102148 | EDGAR | — |
| 2025-05-05 | 2025-03-31 | 0000950170-25-063634 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124758 | EDGAR | — |
| 2024-08-05 | 2024-06-30 | 0000950170-24-090828 | EDGAR | — |
| 2024-05-06 | 2024-03-31 | 0000950170-24-053697 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0000950170-23-059470 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0000950170-23-039178 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-018976 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0000950170-22-022710 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016143 | EDGAR | — |
| 2022-05-02 | 2022-03-31 | 0000950170-22-006901 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-01 | 0001193125-26-135669 | EDGAR | 1K words |
| 2026-02-23 | 0001193125-26-062421 | EDGAR | — |
| 2026-02-17 | 0001193125-26-053009 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009744 | EDGAR | — |
| 2025-12-31 | 0001193125-25-337644 | EDGAR | — |
| 2025-11-03 | 0001193125-25-261651 | EDGAR | — |
| 2025-08-20 | 0001579428-25-000007 | EDGAR | — |
| 2025-08-04 | 0000950170-25-101624 | EDGAR | — |
| 2025-06-10 | 0000950170-25-084098 | EDGAR | — |
| 2025-06-09 | 0000950170-25-083793 | EDGAR | — |
295 total filings indexed. 263 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001579428 |
| Ticker | AXSM |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.axsome.com |
| Listed | 2015-11-19 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report